Skip to main content

Biopharma Due Diligence

A global biopharma company was evaluating an acquisition whose potential indications ranged from gastrointestinal disorders to ophthalmology. With a key leader out on vacation and the deadline for a non-binding term sheet drawing near, the company’s head of Commercial Business Development turned to Business Talent Group.

In the span of a few days, we delivered a two-person team to help the company extend and finalize its commercial evaluation. A biotech investment specialist customized a model that looked at multiple scenarios and helped size patient populations across different indications. An analyst assessed market access and competitive dynamics. A week later, the team had the figures it needed to make a successful bid; they are now proceeding to the next phase of the acquisition.

About the Author

Leah Hoffmann is a former journalist who has worked for Forbes.com and The Economist. She is passionate about clear thinking, sharp writing, and strong points of view.

Profile Photo of Leah Hoffmann